Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for systemic lupus erythematosus: A Phase 2 randomized controlled trial
Arthritis Rheumatol 2024 DOI: 10.1002/art.42926 Epub ahead of print
Daily oral upadacitinib 30 mg and ABBV-599 high dose (elsubrutinib 60 mg QD + upadacitinib 30 mg) were effective in multiple outcome measures including disease activity, flares, time to first flare, and joint counts.
Keywords:
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: A multicentre, open-label, randomised controlled trial
Lancet Rheumatol 224;6(3):e168–77 DOI 10.1016/S2665-9913(23)00320-X
Mycophenolate mofetil (MMF) withdrawal was not significantly inferior to MMF maintenance through Week 60 in patients with SLE that had been treated with MMF for ≥1 year.
Keywords:
Safety and Efficacy of Long-term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial
Arthritis Rheumatol. 2023;76(1):59–67 DOI: 10.1002/art.42657
AURORA 2 demonstrated the safety and tolerability of continued administration of voclosporin over 3 years of treatment in patients with LN.
Keywords:
Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis
Arthritis Care Res (Hoboken). 2023 Jul;75(7):1399–1408 DOI: 10.1002/acr.25007
Pooled analysis of data from the AURA-LV phase 2 and AURORA 1 phase 3 trials of voclosporin in patients with active LN demonstrated that significantly more patients achieved a complete renal response at 1 year in the voclosporin than the control group (p<0.0001), with no observation of new safety signals.
Two-Year, Randomised, Controlled Trial of Belimumab in Lupus Nephritis
N Engl J Med. 2020;383(12):1117–28.
LN occurs in 25–60% of patients with SLE. However, patients with LN are often excluded from clinical trials of SLE therapies.